DaVita HealthCare Partners Inc (DVA)

DaVita (DVA) stock is holding steady around $177.80 after reporting strong Q2 2026 earnings, with diluted EPS of $4.02, exceeding estimates. The company also announced a new value-based care partnership with Humana, expanding services for chronic kidney disease patients. This collaboration aligns with DaVita's strategy to move towards integrated, outcome-based kidney care models, reinforcing its long-term revenue mix and operational efficiency.

Labcorp (LH) announced the nationwide rollout of the FDA-cleared Elecsys pTau-217 Alzheimer’s blood test, which can identify amyloid pathology in patients 55 and older with cognitive concerns. This diagnostic innovation expands Labcorp's Alzheimer's testing portfolio and could be a significant growth driver, particularly with the company's push into primary care. Despite potential growth, the company's investment narrative is also subject to ongoing pressures from reimbursement and regulatory changes, such as PAMA.

This article displays the "Enterprise value to revenue forward" metric for DaVita Inc. (NYSE: DVA) on TradingView. It appears to be a financial data point without additional analytical text, presented within the platform's interface. The page provides navigation and links related to financial data, tools, and community features of TradingView.

DaVita Inc. has announced a new value-based care agreement with Humana Inc. to provide comprehensive, coordinated care for Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B-5. This partnership, which began on July 1st, aims to intervene earlier in the disease progression to stabilize kidney function and slow its decline. The program will serve over 10,000 patients, offering coordinated care, education, and support from an interdisciplinary team to address various barriers to care.

DaVita and Humana have expanded their kidney care partnership through a new value-based care agreement covering over 10,000 Medicare Advantage members with chronic kidney disease (CKD) stages 3B through 5. This program, launched on July 1, builds on an existing collaboration that previously focused on end-stage kidney disease, now aiming to preserve kidney function, slow disease progression, and reduce hospitalizations through coordinated care provided by DaVita Integrated Kidney Care. The initiative emphasizes earlier intervention and comprehensive support for patients, including nutrition, transportation, and mental health assistance.